Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366171904> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4366171904 endingPage "S109" @default.
- W4366171904 startingPage "S109" @default.
- W4366171904 abstract "Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, Japan, and other countries for the treatment of adults with moderate-to-severe plaque psoriasis. Deucravacitinib was well tolerated and efficacious in two global phase 3 trials, POETYK PSO-1 (NCT03624127) and PSO-2 (NCT03611751), as well as in POETYK PSO-3 (NCT04167462), a phase 3 trial in patients from mainland China, Taiwan, and South Korea. Here, we report onset of action and maintenance of response to deucravacitinib in PSO-3. Deucravacitinib (n=146) was associated with significantly larger mean changes from baseline vs placebo (n=74) by Week 1 in Psoriasis Area and Severity Index (PASI) and the more convenient measure in clinic, body surface area by static Physician’s Global Assessment (BSA×sPGA) (−2.8,P<0.002 and −10.1, P<0.04, respectively) and by Week 2 in BSA involvement (−3.3, P<0.0007). Achievement of PASI 75 and sPGA score of 0 (clear) or 1 (almost clear) was significantly higher with deucravacitinib vs placebo by Week 4 (P<0.006 and P<0.0006, respectively). Responses were maintained through 52 weeks with continuous deucravacitinib treatment; patients who crossed over from placebo at Week 16 had comparable results at Week 52. Patient-reported outcomes (PSSD, DLQI 0/1) were improved as early as Week 2 with deucravacitinib vs placebo; improvements were maintained through Week 52. Deucravacitinib displayed a rapid onset of action by Week 1 and sustained maintenance of response in Asian patients with moderate to severe plaque psoriasis." @default.
- W4366171904 created "2023-04-19" @default.
- W4366171904 creator A5001152097 @default.
- W4366171904 creator A5008810271 @default.
- W4366171904 creator A5011045762 @default.
- W4366171904 creator A5014318893 @default.
- W4366171904 creator A5019332077 @default.
- W4366171904 creator A5024597749 @default.
- W4366171904 creator A5030645001 @default.
- W4366171904 creator A5065114762 @default.
- W4366171904 creator A5067270059 @default.
- W4366171904 creator A5079068488 @default.
- W4366171904 date "2023-05-01" @default.
- W4366171904 modified "2023-09-28" @default.
- W4366171904 title "637 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: Onset of action and maintenance of response in the phase 3 POETYK PSO-3 trial" @default.
- W4366171904 doi "https://doi.org/10.1016/j.jid.2023.03.644" @default.
- W4366171904 hasPublicationYear "2023" @default.
- W4366171904 type Work @default.
- W4366171904 citedByCount "0" @default.
- W4366171904 crossrefType "journal-article" @default.
- W4366171904 hasAuthorship W4366171904A5001152097 @default.
- W4366171904 hasAuthorship W4366171904A5008810271 @default.
- W4366171904 hasAuthorship W4366171904A5011045762 @default.
- W4366171904 hasAuthorship W4366171904A5014318893 @default.
- W4366171904 hasAuthorship W4366171904A5019332077 @default.
- W4366171904 hasAuthorship W4366171904A5024597749 @default.
- W4366171904 hasAuthorship W4366171904A5030645001 @default.
- W4366171904 hasAuthorship W4366171904A5065114762 @default.
- W4366171904 hasAuthorship W4366171904A5067270059 @default.
- W4366171904 hasAuthorship W4366171904A5079068488 @default.
- W4366171904 hasBestOaLocation W43661719041 @default.
- W4366171904 hasConcept C126322002 @default.
- W4366171904 hasConcept C142724271 @default.
- W4366171904 hasConcept C16005928 @default.
- W4366171904 hasConcept C204787440 @default.
- W4366171904 hasConcept C27081682 @default.
- W4366171904 hasConcept C2776173921 @default.
- W4366171904 hasConcept C2777011040 @default.
- W4366171904 hasConcept C2780564577 @default.
- W4366171904 hasConcept C3020604521 @default.
- W4366171904 hasConcept C46821324 @default.
- W4366171904 hasConcept C535046627 @default.
- W4366171904 hasConcept C71924100 @default.
- W4366171904 hasConcept C90924648 @default.
- W4366171904 hasConceptScore W4366171904C126322002 @default.
- W4366171904 hasConceptScore W4366171904C142724271 @default.
- W4366171904 hasConceptScore W4366171904C16005928 @default.
- W4366171904 hasConceptScore W4366171904C204787440 @default.
- W4366171904 hasConceptScore W4366171904C27081682 @default.
- W4366171904 hasConceptScore W4366171904C2776173921 @default.
- W4366171904 hasConceptScore W4366171904C2777011040 @default.
- W4366171904 hasConceptScore W4366171904C2780564577 @default.
- W4366171904 hasConceptScore W4366171904C3020604521 @default.
- W4366171904 hasConceptScore W4366171904C46821324 @default.
- W4366171904 hasConceptScore W4366171904C535046627 @default.
- W4366171904 hasConceptScore W4366171904C71924100 @default.
- W4366171904 hasConceptScore W4366171904C90924648 @default.
- W4366171904 hasIssue "5" @default.
- W4366171904 hasLocation W43661719041 @default.
- W4366171904 hasOpenAccess W4366171904 @default.
- W4366171904 hasPrimaryLocation W43661719041 @default.
- W4366171904 hasRelatedWork W1978428707 @default.
- W4366171904 hasRelatedWork W2126375175 @default.
- W4366171904 hasRelatedWork W2170270641 @default.
- W4366171904 hasRelatedWork W2337434357 @default.
- W4366171904 hasRelatedWork W2361583958 @default.
- W4366171904 hasRelatedWork W2545526290 @default.
- W4366171904 hasRelatedWork W2602145888 @default.
- W4366171904 hasRelatedWork W2954778191 @default.
- W4366171904 hasRelatedWork W4255680485 @default.
- W4366171904 hasRelatedWork W4297878981 @default.
- W4366171904 hasVolume "143" @default.
- W4366171904 isParatext "false" @default.
- W4366171904 isRetracted "false" @default.
- W4366171904 workType "article" @default.